Mifeprex (mifepristone) / Danco Laboratories, BioPro Medical - LARVOL DELTA

Actionable resistance mechanisms in osteosarcoma uncovered by the elucidate spatial biomarker platform (AACR 2026) - "Proteomic data identified phenotypic and spatial features associated with therapeutic response, while transcriptomic profiling on the same slide elucidated molecular pathways underlying these tissue-level patterns.ResultsApplication of this platform to an osteosarcoma patient sample uncovered two actionable mechanisms of therapeutic resistance:1.FAP-mediated T-cell exclusion: Excess fibroblast activation protein (FAP) expression on tumor-associated stromal cells formed a physical and immunoregulatory barrier preventing T-cell infiltration. Clinical treatment of the patient with a FAP-targeted radioligand inhibitor resulted in a positive therapeutic outcome.2.CD163⁺ macrophage survival pathway: Same-slide multiomic analysis identified a survival mechanism specific to CD163⁺ tumor-associated macrophages via PAQR6, which was targetable using mifepristone, suggesting a second actionable therapeutic avenue.These findings demonstrate that same-slide spatial multiomics,..."

Biomarker • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CD163 • FAP

Mifepristone-mediated induction of PD-L1 expression in hormone receptor positive breast tumors (AACR 2026) - P=N/A | "MIPRA trial-participating patients exhibit a significant increase in the score of PD-L1 detection after MIFE treatment (p<0.05).These results suggest that endocrine therapy with MIFE can reprogram the immune landscape of luminal breast tumours in patients, promoting a "hot" TME, increasing TILs and PD-L1 expression. This MIFE-mediated immune fitness may sensitize luminal tumours to ICI therapy and open new therapeutic avenues for this prevalent breast cancer subtype."

IO biomarker • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1 • PGR

Clinical outcomes of single-agent mifepristone exposures reported to U.S. Poison Centers: a ten-year review of the National Poison Data System® (2015-2024). (PubMed, Clin Toxicol (Phila)) - "Mifepristone is a 19-nor steroid that functions as a progesterone and glucocorticoid receptor antagonist with multiple uses approved by the United States Food and Drug Administration. No major effects, critical care admissions, or deaths were identified. These findings suggest that single-agent mifepristone exposures rarely result in major effects and generally follows a benign clinical course."

Clinical data • Journal • Critical care • Otorhinolaryngology • Pain • Vertigo

Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769) (SABCS 2025) - P2 | " This is a randomized phase II trial; 201 patients (pts) will be randomized in a 1:1:1 fashion to enza, enza plus mif, or TPC (carboplatin, paclitaxel, eribulin, or capecitabine). Pts must have normal organ function and no history of brain mets. As of 7/9/2025, 19 of 201 pts have begun protocol-specified tx."

Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AR • CTCs • ER • HER-2 • PGR

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. (PubMed, Geroscience) - "This study underscores the importance of rigorous, multi-site testing and highlights the challenges of translating promising initial findings into consistent lifespan benefits at other doses or with alternate starting ages. These results suggest that timing and dosage are critical variables in aging intervention studies and reinforce the need for cautious interpretation of single-site or single-cohort findings."

Journal • Preclinical

Impact of corticosteroid administration on glioblastoma progression before and after adjuvant treatments: recent updates on contradictory findings and mechanistic interactions. (PubMed, Front Oncol) - "Corticosteroids, particularly dexamethasone (DEX), are widely used in the supportive management of glioblastoma and grade 4 astrocytoma because of their rapid efficacy in reducing vasogenic cerebral edema and alleviating neurological symptoms...While experimental studies have reported anti-proliferative and anti-migratory effects of DEX in glioma models, accumulating clinical and translational evidence suggests detrimental interactions with radiotherapy (RT) and temozolomide (TMZ), particularly when steroids are administered at higher doses or during RT...Emerging therapeutic strategies, including agents targeting epigenetic regulators, metabolic pathways, or repurposed drugs such as Riluzole, Metformin, Mifepristone, and Chlorpromazine, show promise in mitigating steroid-associated resistance to TMZ. Collectively, these findings emphasize the complex, context-dependent role of corticosteroids in glioblastoma or grade 4 astrocytoma and emphasize the need for optimized..."

Journal • Review • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Short-Interval Mifepristone-Misoprostol Versus Misoprostol Alone for Second-Trimester Abortion: A Retrospective Observational Study. (PubMed, Cureus) - "Conclusion In women with second-trimester fetal demise, a short-interval mifepristone-misoprostol regimen is associated with significantly higher success rates and fewer complications compared to misoprostol alone. These findings support the effectiveness and safety of short-interval combination therapy in this clinical setting."

Journal • Observational data • Retrospective data • Infectious Disease • Pain

Computational modeling-directed combination treatment with etanercept and mifepristone mitigates neuroinflammation in a mouse model of Gulf War Illness. (PubMed, PLoS One) - "Supporting results from the computational modeling of this treatment, we found that this drug combination significantly alleviates the underlying neuroinflammation associated with Gulf War Illness. The fusion of computational and in vivo preclinical treatment evaluation may provide a highly useful and translationally relevant means by which to identify successful treatment paradigms for Gulf War Illness."

Journal • Preclinical • Inflammation

Etomidate, Ketoconazole, and Mitotane for Cushing Disease due to Adrenocortical Carcinoma (SCCM 2026) - "Triple therapy (carboplatin, etoposide, and doxorubicin) was considered but not initiated due to poor functional status...Osilodrostrat, mifepristone, metyrapone, and pasireotide were considered but restricted by primary disease and cost...EI's are safe and effective to reduce cortisol quickly, but many institutions and staff are unfamiliar with its use as a continuous infusion. Many challenges still exist for this difficult and rare disease."

Adrenal Cortex Carcinoma • Cushing’s Disease • Diabetes • Endocrine Disorders • Genito-urinary Cancer • Oncology • Rare Diseases • Solid Tumor

GR/HDAC3 Regulates Npas4 Signaling Pathway and Mediates Cognitive Impairment in Prenatal Hypoxia Male Offspring. (PubMed, FASEB J) - "By acting as a GR receptor antagonist, Mifepristone (MIF) mitigates ameliorated neurogenesis and cognitive impairment in the hippocampus of PH male offspring through the GR/HDAC3-Npas4 pathway. Thus, our study reveals that the GR/HDAC3-Npas4 signaling pathway is implicated in reduced hippocampal neurogenesis and cognitive impairment in PH male offspring. This research provides support for the pathogenesis of fetal cognitive impairment caused by PH."

Journal • Alzheimer's Disease • Cognitive Disorders • HDAC3

Low-dose mifepristone for the management of refractory heavy menstrual bleeding in women with bleeding disorders: a retrospective study. (PubMed, BMC Womens Health) - "In this retrospective cohort, low-dose mifepristone was associated with improved bleeding control and acceptable tolerability. It may serve as a potential bridge therapy for women with BD and refractory HMB. Prospective controlled studies are warranted."

Journal • Retrospective data • Cardiovascular • Gynecology • Hematological Disorders • Thrombocytopenia • Women's Health

Intrapartum posterior cul-de-sac rupture, a clinical enigma: a case report. (PubMed, Int J Surg Case Rep) - "Her cervical os was closed, so labor was induced with mifepristone followed by misoprostol...It is crucial to suspect the possibility of a hidden vaginal wall rupture during labor, particularly when there is unexplained acute pain. Future studies should compare outcomes across parity groups and evaluate induction-related risk."

Journal • Gynecology • Infectious Disease • Obstetrics • Pain

FIRST CLINICAL TEST OF A CONTINUOUS CORTISOL SENSOR (ATTD 2026) - "A continuous cortisol sensor (CCS) could assist hypercortisolism drug titration (e.g. mifepristone) or as a new input into automated insulin delivery systems to account for sleep/stress insulin sensitivity changes. Biolinq has recently created a continuous cortisol sensor using a new electrochemical sensing technology... This study demonstrated the world's first in-vivo clinical study of an intradermal cortisol sensor."

Clinical • First-in-human

Pharmacologic inhibition of the Glucocorticoid Receptor synergizes with immunotherapy to prevent metastatic recurrence in pre-clinical models (AACR-IO 2026) - "Pharmacologic inhibition of GR using the FDA-approved drug Mifepristone in combination with anti-PD1 immunotherapy drastically reduced DTC metastasis and extended mouse lifespan...In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B016."

Metastases • Preclinical • Breast Cancer • Solid Tumor • Triple Negative Breast Cancer • CD8 • FASLG

American Academy of Clinical Toxicology position statement on the appropriate scheduling of drugs. (PubMed, Clin Toxicol (Phila)) - "The position of the American Academy of Clinical Toxicology (AACT), endorsed by the American College of Medical Toxicology (ACMT) is as follows: The American Academy of Clinical Toxicology supports appropriate scheduling of drugs in adherence to the scheduling guidelines specified by the Controlled Substances Act (CSA). Scheduling medications without following established best practices and existing Drug Enforcement Agency (DEA) guidelines may limit access to care and represents a threat to public safety."

Journal • Review

Comparative analysis of social issues toward medical abortion using mifepristone in South Korea and the United States: Topic modeling and sentiment analysis. (PubMed, PLoS One) - "The United States coverage was polarized, encompassing clinical, legal, and access-related debates, whereas Korean articles prioritized access barriers, safety concerns, and the urgency for domestic approval, reflecting predominantly negative sentiments related to cultural stigma. This study highlights differences in the media portrayals and public perceptions of mifepristone between South Korea and the United States, underscoring the influence of regulatory contexts, public concerns and cultural attitudes on medical abortion discourse."

Journal

TIMING OF SERIOUS ADVERSE EVENTS FOLLOWING MIFEPRISTONE ABORTION IN US COMMERCIAL AND MEDICAID POPULATIONS (ISPOR 2026) - "Clinically important AEs following medication abortion are rare; <1% of abortions lead to major AEs requiring hospitalization. Transparent, real-world data are critical for contextualizing clinical risk and guiding evidence-based policy decisions to ensure that abortion regulations are proportionate to measured clinical risks."

Adverse events • Clinical • Medicaid • Reimbursement • Serious adverse event • US reimbursement • Hematological Disorders • Infectious Disease • Septic Shock

Emergency contraception (ISGE 2026) - "The recommended options for oral EC are ulipristal acetate 30mg and levonorgestrel 1.5 mg...Mifepristone is also effective for EC, but a registered EC product is only available in a few countries...Knowledge on the mechanisms of action of ECP could help to optimize their use and give realistic expectations on their effectiveness. We have utilized this knowledge in the development of new ECP or flexible on demand options with wider window of action resulting in increased efficacy."

Long-acting Reversible Contraceptives

Prevalence of long-term contraception in induced abortion in private msi mexico clinics (ISGE 2026) - "OBJECTIVE To compare acceptance and satisfaction rates of long-acting contraceptive methods in patients undergoing first trimester induced abortion, either surgical or medical with mifepristone and misoprostol...Copper IUD selection was 3 times higher compared with other LARC methods. Health care access may facilitate the uptake of contraceptives."

Long-acting Reversible Contraceptives

Effectiveness and Safety of Mifepristone–Misoprostol Regimen for Second Trimester Pregnancy Termination (ISGE 2026) - "The combination of mifepristone and misoprostol is a highly effective and safe method for second-trimester pregnancy termination in cases of fetal death or malformation. The regimen demonstrated a high success rate, acceptable side-effect profile, and minimal need for surgical intervention, supporting its routine clinical use in obstetric–gynecologic units."

Clinical • Hematological Disorders • Infectious Disease • Obstetrics

Glucocorticoid Receptor Blockade Reverses Heroin and Alcohol Withdrawal-Induced Hyperalgesia in Rats. (PubMed, Neuropharmacology) - "These findings reveal sex- and nociception modality-specific differences in alcohol and opioid withdrawal-induced hyperalgesia and highlight GR signaling as a potential therapeutic target for managing withdrawal-related pain."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • Substance Abuse

Undiagnosed placenta accreta spectrum complicated by massive haemorrhage during mid-trimester medical termination of pregnancy: a case report. (PubMed, Case Rep Womens Health) - "Following counselling, medical termination of pregnancy was initiated using mifepristone and misoprostol...It also underscores the potential for abrupt, life-threatening haemorrhage during medical termination of pregnancy in women with multiple previous caesarean deliveries. As caesarean rates rise, clearer guidance is needed regarding risk stratification, imaging pathways, and procedural planning for mid-trimester abortion to minimise maternal morbidity."

Journal • Cardiovascular • Critical care • Gynecology • Obstetrics

Multi-omics analysis reveals steroid hormone biosynthesis as a key pathway in advanced maternal age threatened abortion. (PubMed, Biol Reprod) - "Disruption of steroid hormone biosynthesis represents central molecular feature to AMA-TA. Integrated multi-omics analysis offers mechanistic insight and supports the development of biomarkers and therapeutic targets for AMA-TA."

Journal • Metabolic Disorders

Thioxanthone-photocatalyzed aerobic oxidation of N,N-dimethylanilines to N-formyl anilines under visible light. (PubMed, Org Biomol Chem) - "The methodology is operationally simple, scalable, and compatible with structurally diverse substrates. Its synthetic utility was further demonstrated through late-stage functionalization of value added molecules, including Padimate O, Thioflavin T, Mifepristone and Tropinone."

Journal

Self-managed abortion practices and post-abortion care experiences among women of reproductive age in Southwest Nigeria. (PubMed, Afr J Reprod Health) - "Women used various drugs such as misoprostol, mifepristone, Mifestad, Cytotec, white quinine, and a combination of 'alabukun' and lime to induce abortion...In conclusion, self-managed abortion poses challenges related to accessing safe drugs and resorting to the use of alternative remedies to prescription-based drugs. At least as a harm reduction strategy, it is crucial to ensure the availability of safe abortion medications to discourage women from choosing risky self-managed abortion methods as alternatives."

Journal